At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Post-Mkt 06-30 17:17:02 EDT
0.5154
-0.0107
-2.03%
盘后0.5807
+0.0653+12.67%
17:16 EDT
High0.5998Low0.4700Vol25.42M
Open0.5610D1 Closing0.5261Amplitude24.67%
Mkt Cap17.22MTradable Cap5.26MTotal Shares33.41M
T/O15.22MT/O Rate249.21%Tradable Shares10.20M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Pasithea Therapeutics announces updated data from PAS-004 trial
TIPRANKS  ·  06-30 19:15
Pasithea Therapeutics announces updated data from PAS-004 trial
Pasithea Therapeutics Corp - Protocol Amendment Extends Dose Escalation up to 52mg for Pas-4
THOMSON REUTERS  ·  06-30 19:00
Pasithea Therapeutics Corp - Protocol Amendment Extends Dose Escalation up to 52mg for Pas-4
Pasithea Therapeutics Corp - Pas-4 Shows Favorable Safety Profile with Only Grade 1 or 2 Adverse Events
THOMSON REUTERS  ·  06-30 19:00
Pasithea Therapeutics Corp - Pas-4 Shows Favorable Safety Profile with Only Grade 1 or 2 Adverse Events
Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics
THOMSON REUTERS  ·  06-30 19:00
Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion
THOMSON REUTERS  ·  06-30 19:00
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
GlobeNewswire  ·  06-30 19:00
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Major Investor Quietly Boosts Stake in Pasithea Therapeutics
TIPRANKS  ·  06-23
Major Investor Quietly Boosts Stake in Pasithea Therapeutics
Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000
Reuters  ·  06-22
Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)
TIPRANKS  ·  06-16
Analysts Are Bullish on Top Healthcare Stocks: Pasithea Therapeutics Corp (KTTA), Adaptive Biotechnologies (ADPT)
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-16
Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment
MT Newswires Live  ·  06-16
Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment
Pasithea Therapeutics expands PAS-004 Phase 1/1b NF1 trial with higher dose cohorts
Reuters  ·  06-16
Pasithea Therapeutics expands PAS-004 Phase 1/1b NF1 trial with higher dose cohorts
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial
THOMSON REUTERS  ·  06-16
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial
Pasithea Therapeutics - Amendments Add 24Mg and 32Mg Dose Levels and Backfilling of Cohorts in Phase 1/1B Trial
THOMSON REUTERS  ·  06-16
Pasithea Therapeutics - Amendments Add 24Mg and 32Mg Dose Levels and Backfilling of Cohorts in Phase 1/1B Trial
Pasithea Therapeutics - on Track to Release Interim Nf1 Data Update in Q4 2026
THOMSON REUTERS  ·  06-16
Pasithea Therapeutics - on Track to Release Interim Nf1 Data Update in Q4 2026
Pasithea Therapeutics - Amendments Extend Treatment to 18 Months and Add Mri Scans and Cn Measurements
THOMSON REUTERS  ·  06-16
Pasithea Therapeutics - Amendments Extend Treatment to 18 Months and Add Mri Scans and Cn Measurements
Pasithea Therapeutics to exhibit at Children’s Tumor Foundation NF Conference
Reuters  ·  06-15
Pasithea Therapeutics to exhibit at Children’s Tumor Foundation NF Conference
Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
Reuters  ·  06-02
Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
THOMSON REUTERS  ·  06-02
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis
TIPRANKS  ·  05-30
Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

Introduction

Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--